

Confirmed Speakers

Vorapaxar Discovery and Clinical Benefits



Dr Patrick ANDRE
(MERCK & CO., Kenilworth, United States)

Discovery and Development of Bedaquiline: A Rocky Road



Prof. Koen ANDRIES
(JANSSEN PHARMACEUTICA NV, Beerse, Belgium)

High Affinity Bicyclic Peptides: Application to Payloads in Oncology



Dr Gavin BENNETT
(BICYCLE THERAPEUTICS, Cambridge, United Kingdom)

A Novel Retinoic Acid Receptor Agonist for Dermatological Indications with Specific Design Parameters for Topical Administration to Manage Safety



Dr Claire BOUIX-PETER
(GALDERMA R&D, Sophia-Antipolis, France)

Panellist 2



Prof. Chas BOUNTRA
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

Structure-Based Design of Inhibitors of Factor XIa



Dr James CORTE
(BRISTOL MYERS SQUIBB, Princeton, United States)

Sharing Compound Collections: UCB's First Experiences from the European Lead Factory



Dr Jeremy DAVIS
(UCB, Slough, United Kingdom)

Science, Business & Innovation in Medicinal Chemistry



Prof. Iwan DE ESCH
(VU AMSTERDAM, Amsterdam, The Netherlands)

Inhaled PDE4 Inhibitors with Low Emetic Potential and Long Duration of Action for the Treatment of COPD

Confirmed Speakers



Dr Chris DE SAVI
(ASTRAZENECA R&D, Boston, United States)

Locally-acting ROCK Inhibitors for the Treatment of Eye Diseases



Dr Olivier DEFERT
(AMAKEM, Loos, France)

Revealing The Structural Basis for GPCR Drug Action through Atomic-Level Simulation



Prof. Ron DROR
(STANFORD UNIVERSITY, Stanford, United States)

The Discovery Of A New Validated Target For Tuberculosis Via Phenotypic Screening



Ms Raquel FERNANDEZ
(GLAXOSMITHKLINE, Tres Cantos, Spain)

Drug Target Residence Time: HSP90, a Model to Gain Insight into the Molecular Mechanism of Binding



Dr Matthias FRECH
(MERCK, Darmstadt, Germany)

Targeting Protein-Protein Interactions in the Heat Shock Protein 70 (Hsp70) Complex



Prof. Jason GESTWICKI
(UNIVERSITY OF CALIFORNIA, San Francisco, United States)

Kinetics in Drug discovery - A Case for the Adenosine Receptors



Mr Dong GUO
(LEIDEN UNIVERSITY, Leiden , The Netherlands)

The Discovery of Chemical Probes for Bromodomain Containing Proteins Prize winner EFMC-YMCS 2014



Dr Duncan HAY
(EVOTEC, Abingdon, United Kingdom)

Discovery & Optimisation of Novel Antagonists to the Human Neurokinin-3 Receptor for the Treatment of Sex-Hormone Disorders: From Hit to Clinic



Dr Hamid HOVEYDA
(EUROSCREEN, Woluwe-Saint-Lambert, Belgium)

Novel JAK Inhibitors for Inhaled and Topical Delivery

Confirmed Speakers



Dr Peter JONES
(PFIZER, Cambridge, United States)

Discovering A Potent Allosteric Kinase Modulator Employing A Computational And Synthetic Toolbox



Mr Edwin KROON
(UNIVERSITY OF GRONINGEN, Groningen, The Netherlands)

Towards 3rd Generation Antihistamines: Fact or Fiction?



Prof. Rob LEURS
(VU UNIVERSITY AMSTERDAM, Amsterdam, The Netherlands)

The Role of CXCR4 Modulators in Controlling HIV Entry, Stem Cell Mobilisation and Certain Types of Cancer



Prof. Dennis LIOTTA
(EMORY UNIVERSITY, Atlanta, United States)

Discovery and Optimisation of Bioactive Macrocycles from DNA-Encoded Libraries



Dr Patrick MCENANEY
(THE SCRIPPS RESEARCH INSTITUTE, La Jolla, United States)

Privileged Structures Unlocking Therapeutic Target Families



Dr Gerhard MUELLER
(MERCACHEM, Basel, Germany)

Panellist 1



Prof. Christa MÜLLER
(UNIVERSITY OF BONN, Bonn, Germany)

Translating Medicinal Chemistry Research into Targeted Therapeutics. Building on Academic Knowledge



Prof. Roberto PELLICCIARI
(UNIVERSITY OF PERUGIA, Corciano, Italy)

Sanford-Burnham's Experience with the NIH's Molecular Libraries Program



Dr Anthony PINKERTON
(SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE, La Jolla, United States)

Confirmed Speakers

Targeting Factor XII in Thrombosis and Inflammation



Prof. Thomas RENNE
(KAROLINSKA INSTITUTET, Stockholm, Sweden)

Measuring The Dynamics Of Target Engagement Inside Cells Using Bret



Mr Matthew ROBERS
(PROMEGA, Madison, United States)

Story of the Hsp27 Inhibitor Apatorsen



Dr Palma ROCCHI
(MARSEILLE CANCEROLOGY RESEARCH CENTER, Marseille, France)

Exploring Macrocycles for Protein-protein Interaction Targets: the Discovery of Novel Bifunctional XIAP Antagonists



Dr Nick TERRETT
(ENSEMBLE THERAPEUTICS CORPORATION, Kriens, Switzerland)

Discovery of Highly Efficacious Potentiators for the Treatment of Cystic Fibrosis



Dr. Steven VAN DER PLAS
(ITEOS THERAPEUTICS, Belgium)

The Design of mGlu2 Negative Allosteric Modulators for the Treatment of Neuropsychiatric Disorders



Dr Michiel VAN GOOL
(JANSSEN R&D, Toledo, Spain)

Regulated Necrosis: Disease Relevance and Therapeutic Opportunities



Prof. Peter VANDENABEELE
(UNIVERSITY OF GHENT, Ghent, Belgium)

Selective JAK1 Inhibitor for the Treatment of Autoimmune Diseases



Dr Michael L. VAZQUEZ
(PFIZER, Cambridge, United States)

Update on Hsp90 Inhibitors as Cancer Therapeutics



Dr Weiwen YING
(SYNTA PHARMACEUTICALS, Lexington, United States)